Axsome: AXSM Stock Down Despite ADHD Study Meeting Primary Endpoint
Axsome's phase III FOCUS study, evaluating solriamfetol for treating attention deficit hyperactivity disorder, meets its primary and key secondary endpoints.
Read full article »
Axsome is a New York-based biopharmaceutical company that researches and develops novel therapies for the treatment of central nervous system disorders.
Read more